

# MCI in Latin American Countries

MCI 2017

Mount Sinai Medical Center  
Miami Beach, Florida

*Ricardo Nitrini, USP, Brazil*

# MCI in LAC. Reasons for a difference

---

- Genetics of the population
- Low education (low cognitive reserve)
- Cultural differences (meaning of the cognitive decline in aging)
- Control of risk factors (low SES; low education)
- Difficulty of assessment (illiteracy/low education)

# Dementia in LAC

- Higher prevalence than in developed countries (Prince et al., 2013)



*Alzheimer's & Dementia* 9 (2013) 63–75

Alzheimer's  
&  
Dementia

Review Articles

The global prevalence of dementia: A systematic review  
and metaanalysis

Martin Prince<sup>a,\*</sup>, Renata Bryce<sup>a</sup>, Emiliano Albanese<sup>a,b</sup>, Anders Wimo<sup>c,d</sup>,  
Wagner Ribeiro<sup>a,e</sup>, Cleusa P. Ferri<sup>a,e</sup>




Fig. 1. Estimated prevalence of dementia for those aged  $\geq 60$  years, standardized to the Western Europe population, by Global Burden of Disease region.

# Prevalence of dementia in Latin America:

A collaborative study of population-based cohorts. (8 studies from 6 countries)

---

**Brazil (3)**

**Chile**

**Cuba**

**Peru**

**Uruguay**

**Venezuela**



Nitrini R, Bottino CMC, Albala C, Custodio Capuñay NS, Ketzoian C, Rodriguez JJJ, Maestre GE, Ramos-Cerqueira AT, Caramelli P.

# Latin American data compared with a systematic review of dementia prevalence (21 studies)

<b>Age</b>	<b>LA studies</b>	<b>Systematic review</b>
	Mean (%) (95% CI)	Mean (%) (95% CI)
<b>65-69</b>	<b>2.4 (2.1-2.7)</b>	<b>1.2 (0.8 – 1.5)</b>
70-74	3.6 (3.1-4.0)	3.7 (2.6 – 4.7)
75-79	7.0 (6.3-7.6)	7.9 (6.2 – 9.5)
80-84	11.8 (10.8-12.9)	16.4 (13.8 – 18.9)
85-89	20.2 (18.6-21.7)	24.6 (20.5 – 28.6)
90-94	33.0 (29.9-36.2)	39.9 (34.4 – 45.3)
> 95	-	54.8 (45.6 – 63.9)

# Dementia in LAC

---

- 1) High prevalence of dementia in Latin America
- 2) Dementia may start earlier in Latin America  
(due to low cognitive reserve)

# High frequency of vascular dementia in a neuropathological study



BASIC RESEARCH

## Prevalence of dementia subtypes in a developing country: a clinicopathological study

Lea T. Grinberg,<sup>I,II</sup> Ricardo Nitrini,<sup>III</sup> Claudia K. Suemoto,<sup>IV</sup> Renata Eloah de Lucena Ferretti-Rebustini,<sup>V</sup> Renata E. P. Leite,<sup>I</sup> Jose Marcelo Farfel,<sup>IV</sup> Erika Santos,<sup>I</sup> Mara Patricia Guilhermino de Andrade,<sup>I,VI</sup> Ana Tereza Di Lorenzo Alho,<sup>I,VI</sup> Maria do Carmo Lima,<sup>I,VI</sup> Katia C. Oliveira,<sup>I</sup> Edilaine Tampellini,<sup>I,VI</sup> Livia Polichiso,<sup>I,VI</sup> Glaucia B. Santos,<sup>I,VI</sup> Roberta Diehl Rodriguez,<sup>I</sup> Kenji Ueda,<sup>VII</sup> Carlos A. Pasqualucci,<sup>I</sup> Wilson Jacob-Filho<sup>IV</sup>

2013



<b>Author, year/country</b>	<b>N</b>	<b>AD</b>	<b>AD+VaD</b>	<b>VaD</b>	<b>LBD</b>	<b>FTD</b>	<b>Others</b>
<b>Galasko, 1994, USA</b>	<b>170</b>	<b>56.5</b>	<b>7.1</b>	<b>2.4</b>	<b>22.4</b>	<b>NR</b>	<b>11.8</b>
<b>Victoroff, 1995, USA</b>	<b>196</b>	<b>44.9</b>	<b>12.8</b>	<b>4.6</b>	<b>6.6</b>	<b>NR</b>	<b>31.1</b>
<b>Jellinger, 1996, Austria</b>	<b>540</b>	<b>65.0</b>	<b>4.1</b>	<b>8.5</b>	<b>6.1</b>	<b>2.8</b>	<b>13.5</b>
<b>Akatsu, 2002, Japan</b>	<b>158</b>	<b>46.2</b>	<b>5.7</b>	<b>21.5</b>	<b>17.7</b>	<b>3.2</b>	<b>5.3</b>
<b>Barker, 2002, USA</b>	<b>382</b>	<b>41.6</b>	<b>11.3</b>	<b>3.1</b>	<b>22.0</b>	<b>4.7</b>	<b>17.3</b>
<b>Fu, 2004, USA</b>	<b>202</b>	<b>63.9</b>	<b>2.5</b>	<b>5.9</b>	<b>11.9</b>	<b>4.0</b>	<b>11.9</b>
<b>Brunnström, 2008, Sweden</b>	<b>524</b>	<b>42.0</b>	<b>21.6</b>	<b>23.7</b>	<b>0.2</b>	<b>4.0</b>	<b>8.6</b>
<b>Grinberg, 2013, Brazil</b>	<b>113</b>	<b>35.4</b>	<b>13.3</b>	<b>21.2</b>	<b>5.3</b>	<b>2.6</b>	<b>22.2</b>

# MCI in population studies in LAC

Author Year	City/Country	N Age	Prevalence of MCI	Journal
Mias et al.	Córdoba/Argentina	418 >50	13.6% (a-MCI: 9.1%)	Rev Neurol, 2007
Henao-Arboleda et al.	Medellin/Columbia	848 >50	9.7% (a-MCI)	Rev Neurol, 2008
Juarez-Cedillo et al.	Mexico C./Mexico	2944 ≥ 60	6.45% (a-MCI: 4.97%)	Dement Ger Cogn Disord, 2012

MCI prevalence (age ≥ 60) in numerous international studies: 12-18%

Petersen, 2016

# Prevalence, Distribution, and Impact of Mild Cognitive Impairment in Latin America, China, and India: A 10/66 Population-Based Study

Ana Luisa Sosa<sup>1</sup><sup>9</sup>, Emiliano Albanese<sup>2</sup><sup>9</sup>, Blossom C. M. Stephan<sup>3</sup>, Michael Dewey<sup>4</sup>, Daisy Acosta<sup>5</sup>, Cleusa P. Ferri<sup>4</sup>, Mariella Guerra<sup>6</sup>, Yueqin Huang<sup>7</sup>, K. S. Jacob<sup>8</sup>, Ivonne Z. Jiménez-Velázquez<sup>9</sup>, Juan J. Llibre Rodríguez<sup>10</sup>, Aquiles Salas<sup>11</sup>, Joseph Williams<sup>12</sup>, Isaac Acosta<sup>1</sup>, Maribella González-Viruet<sup>13</sup>, Milagros A. Guerra Hernandez<sup>14</sup>, Li Shuran<sup>7</sup>, Martin J. Prince<sup>4</sup>, Robert Stewart<sup>4\*</sup>

2012

**Table 3.** Prevalence of aMCI by country, gender, and age group.

Country and Gender	aMCI Prevalence, % (95% CI)				Crude Prevalence (95% CI)	Standardized Prevalence (95%CI) <sup>a</sup>
	65–69 y	70–74 y	75–80 y	80+y	All Age Groups	All Age Groups
<b>Cuba (n)</b>	738	739	582	555	1.8 (1.3–2.3)	1.5 (1.0–1.9)
Males	1.5 (0.0–3.0)	1.8 (0.2–3.4)	0.0 (0.0–0.0)	1.7 (–0.2 to 3.6)	—	—
Females	2.7 (1.3–4.2)	2.6 (1.1–4.0)	1.6 (0.3–2.9)	0.8 (–0.1 to 1.7)	—	—
<b>Dominican Rep. (n)</b>	511	483	345	428	1.4 (0.9–2.0)	1.3 (0.7–1.8)
Males	1.7 (–0.2 to 3.6)	2.2 (0.0–4.4)	2.7 (–0.4 to 5.7)	2.9 (0.1–5.7)	—	—
Females	0.9 (–0.1 to 1.9)	1.7 (0.2–3.1)	0.4 (–0.4 to 1.3)	0.7 (–0.3 to 1.7)	—	—
<b>Peru (n)</b>	538	475	368	386	3.1 (2.3–3.9)	2.6 (1.9–3.3)
Males	5.4 (2.1–8.6)	2.7 (0.3–5.1)	2.1 (–0.3 to 4.5)	4.4 (1.4–7.4)	—	—
Females	2.3 (0.7–3.8)	1.7 (0.2–3.2)	3.6 (1.1–6.0)	3.4 (0.9–5.9)	—	—
<b>Venezuela (n)</b>	813	450	320	236	1.2 (0.7–1.7)	1.0 (0.7–1.4)
Males	1.3 (0.0–2.6)	0.0 (0.0–0.0)	2.6 (–0.3 to 5.5)	0.0 (0.0–0.0)	—	—
Females	1.6 (0.5–2.7)	1.4 (0.0–2.9)	1.5 (–0.2 to 3.1)	0.0 (0.0–0.0)	—	—
<b>Mexico (n)</b>	537	552	384	348	3.2 (2.4–4.1)	2.8 (2.0–3.6)
Males	3.7 (0.8–6.7)	4.3 (1.5–7.0)	5.1 (1.6–8.6)	4.0 (0.8–7.2)	—	—
Females	1.3 (0.2–2.5)	4.1 (2.0–6.2)	3.9 (1.4–6.5)	1.0 (–0.4 to 2.4)	—	—

# Prevalence of a-MCI

Country	Standardized prevalence (95% CI)
Cuba	1.5 (1.0-1.9)
Dominican Republic	1.3 (0.7-1.8)
Peru	2.6 (1.9-3.3)
Venezuela	1.2 (0.7-1.7)
Mexico	2.8 (2.0-3.6)

# Prevalence of MCI in LAC

---

- Range: 1.2 to 13.6%
- Lower than in developed countries?
  
- MCI prevalence (age  $\geq$  60) in numerous international studies: 12-18%

Petersen, 2016

# Cognitive impairment no dementia (CIND)

Authors	City/Country	N/ Age	Prevalence of CIND	Journal
Ortiz et al.	Guadalajara/ Mexico	1142 ≥ 60	13.8%	Curr Gerontol Geriatr Res 2012
Caramelli et al.	Caeté/ Brazil	639 ≥ 75	25.2%	Arq Neuropsiquiatr 2011
César et al.	Tremembé/Br azil	630 ≥ 60	19.8%	Alz Dis Assoc Diseases 2016
Brucki	Amazon river banks/Brazil	163 ≥ 50	7.7%	Dement Neuropsychol 2013

(CIND prevalence in USA and Canada ranges from 17 to 23%. Brucki SMD. Review in Dementia & Neuropsychologia, 2013)

# Incidence of MCI in LAC

---

- The incidence rate for a-MCI was 13.2/1000 persons-years (aged  $\geq 65$ ) in Southern Brazil

Chaves et al., 2009

a-MCI incidence of 8.5-25.9/1000 persons-year in a global systematic review

Ward et al., 2012



Allegri et al. **Annual conversion rate: 13.7%**  
**Role of cognitive reserve in progression from  
mild cognitive impairment to dementia**

**Table 4.** Relative risk predictors for conversion to dementia in multivariate analysis.

Predictor	Hazard ratio	z	p value	95% CI
Age over 75	1.634	2.03	0.043	1.016-2.628
Education less than 12 years	1.640	1.99	0.042	1.075-2.760
Not working	2.409	2.30	0.022	1.137-5.104
Global IQ less than 111	0.964	-2.57	0.010	0.938-0.991
Vocabulary score	3.943	4.42	0.000	2.146-7.237
Naming score less than 51	1.932	2.15	0.032	1.059-3.526
Mini Mental State less than 27	2.947	3.35	0.001	1.566-5.548
MCI amnesic type	2.696	2.44	0.015	1.215-5.977

# Estimation of the risk of conversion of mild cognitive impairment of Alzheimer type to Alzheimer's disease in a south Brazilian population-based elderly cohort: the PALA study

The a-MCI annual conversion rate to AD was 8.5% (CI 95% 3.9–16.1)

**Table 4.** Cox regression – multivariate analysis: MCI diagnosis as main factor, variables age, sex, education, and MMSE as co-variables for the outcome progression to probable AD

PREDICTORS	B	HR (95% CI)	P VALUE
MCI diagnosis*	3.91	49.83 (3.6–698.1)	0.004
MMSE	−0.22	0.80 (0.59–1.092)	0.163
Age	0.04	1.04 (0.91–1.2)	0.579
Sex	−0.18	0.84 (0.15–4.74)	0.843
Education	0.16	1.17 (0.98–1.40)	0.089

Godinho et al.  
Internat Psychogeriatrics 2012

# Tremembé Incidence Study

- 135 cases of CIND were identified In the prevalence study
- 75 cases were reevaluated after  $\approx 3.5$  years

Diagnosis	N	Progression to Dementia	Normal at reevaluation
MCI	60	19 (9.0%/year)	9 (4.28%/year)
CIND (without cognitive complaints)	15	1 (1.9%/year)	5 (9.52%/year)

Cesar et al., unpublished

# Predictors of progression (univariate analysis) in the Tremembé Incidence study

---

- Age
- MMSE
- Phonemic fluency (“p”)
- Clock Drawing Test
- Functional Activities Questionnaire (Pfeffer et al., 1982)

## Progression of MCI to dementia in 3 LA studies

---

- Annual rate from 8.5 to 13.7% (Allegri et al.; Chaves et al.; César et al.)
- Education was a predictor of progression in one of these studies
- 8-15% in most studies (Petersen, 2016)

# Neuropathological study of CDR 0.5 cases

---

- Brain Bank of the Brazilian Aging Study Group
- When there is no death certificate autopsy is mandatory in the city of São Paulo, Brazil
- Brains from deceased individuals aged  $\geq 50$  were collected after a next-of-kin provided information through standardized questionnaires.
- Follows ethical norms and international procedures for pathological diagnosis

Grinberg et al., 2007

Leite, Molina, Diehl-Rodriguez et al. Unpublished

# Neuropathological study of CDR 0.5 cases

---

<b>CDR 0.5</b>	<b>N =51</b>
Gender	27W/24M
Age	72.7 ( $\pm$ 10.6)
Education (schooling-years)	3.8 ( $\pm$ 2.9)
CDR Sum of the boxes	1.8 ( $\pm$ 1.0)

<b>CDR 0.5 Neuropathological diagnosis</b>	<b>N</b>
Alzheimer's disease	8 (1 with LBD)
Vascular Cognitive impairment	15
Lewy Body Disease	3
Argyrophilic grain disease (as the only abnormality)	1
Hippocampal sclerosis	1
Normal (any abnormality)	1
Undetermined	22

Leite, Molina, Diehl-Rodriguez et al. Unpublished



## Primary age-related tauopathy (PART): working classification

---

### 1. Requires:

NFT present with Braak stage  $\leq$  IV (usually III or lower)

### 2. Then subclassify as follows:

Category	Thal A $\beta$ Phase <sup>a</sup>	Other disease associated with NFT <sup>b</sup>
Definite	0	Absent
Possible	1-2	Absent

---

Or Definite when neuritic plaques classified as none in CERAD criteria

Possible when sparse neuritic plaques in CERAD criteria

# MCI with without NP diagnosis

---

Normal and undetermined diagnosis	23 cases
Normal	1
Primary age related tauopathy (PART) definite	10
Primary age related tauopathy (PART) possible	4

# Mild behavioral impairment and risk of dementia

---

- Mild behavioral impairment (MBI): a late-life syndrome with prominent psychiatric and behavioral symptoms in the absence of prominent cognitive symptoms that may also be a dementia prodrome.
- High risk for dementia (mainly FTD)

# Conclusions

---

- More studies are needed to evaluate:
  - Prevalence and incidence of MCI in LAC
  - Influence of education in MCI epidemiology and progression to dementia
  - Vascular cognitive impairment as a frequent cause of MCI in LAC